Alpine Immune Sciences (ALPN)
(Delayed Data from NSDQ)
$64.62 USD
+0.05 (0.08%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $64.65 +0.03 (0.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Balance Sheet
Fiscal Year End for Alpine Immune Sciences, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 327 | 238 | 162 | 106 | 41 |
Receivables | 0 | 0 | 25 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 3 | 5 | 2 | 2 |
Total Current Assets | 330 | 241 | 192 | 107 | 42 |
Net Property & Equipment | 1 | 2 | 2 | 2 | 2 |
Investments & Advances | 41 | 35 | 53 | 26 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 380 | 287 | 256 | 144 | 54 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 4 | 3 | 1 | 2 |
Current Portion Long-Term Debt | 0 | 3 | 5 | 3 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 21 | 14 | 9 | 6 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 16 | 36 | 52 | 32 | 1 |
Total Current Liabilities | 42 | 58 | 70 | 41 | 9 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 39 | 51 | 21 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 3 | 8 | 5 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 52 | 107 | 135 | 82 | 25 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 584 | 404 | 287 | 178 | 117 |
Retained Earnings | -256 | -224 | -166 | -116 | -88 |
Other Equity | 0 | -1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 328 | 179 | 121 | 62 | 29 |
Total Liabilities & Shareholder's Equity | 380 | 287 | 256 | 144 | 54 |
Total Common Equity | 328 | 179 | 121 | 62 | 29 |
Shares Outstanding | 58.10 | 45.90 | 29.20 | 23.80 | 18.50 |
Book Value Per Share | 5.64 | 3.91 | 4.14 | 2.61 | 1.59 |
Fiscal Year End for Alpine Immune Sciences, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 327 | 193 | 204 | 195 |
Receivables | NA | 0 | 0 | 0 | 1 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 2 | 4 | 3 | 3 |
Total Current Assets | NA | 330 | 197 | 207 | 199 |
Net Property & Equipment | NA | 1 | 2 | 2 | 2 |
Investments & Advances | NA | 41 | 34 | 36 | 53 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 380 | 241 | 253 | 262 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 4 | 3 | 2 | 2 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 2 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 21 | 18 | 14 | 12 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 16 | 30 | 37 | 40 |
Total Current Liabilities | NA | 42 | 52 | 53 | 57 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 1 | 18 | 20 | 26 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 52 | 79 | 83 | 93 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 584 | 424 | 420 | 407 |
Retained Earnings | NA | -256 | -262 | -250 | -237 |
Other Equity | NA | 0 | -1 | -1 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 328 | 162 | 169 | 170 |
Total Liabilities & Shareholder's Equity | NA | 380 | 241 | 253 | 262 |
Total Common Equity | 0 | 328 | 162 | 169 | 170 |
Shares Outstanding | 65.50 | 58.10 | 49.20 | 47.90 | 47.90 |
Book Value Per Share | 0.00 | 5.64 | 3.29 | 3.54 | 3.54 |